文献速递类风湿关节炎

接受JAK抑制剂与肿瘤坏死因子抑制剂治疗的类风湿关节炎患者心血管及癌症危险因素患病率:横断面研究

Prevalence of Cardiovascular and Cancer Risk Factors Among Rheumatoid Arthritis Patients Prescribed JAK Inhibitors and Tumor Necrosis Factor Inhibitors: A Cross-Sectional Study.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2024-05-21

研究基于商业保险数据库纳入2019年8月16日至2022年3月31日期间首次 dispensing TNFi 或 JAKi 的类风湿关节炎患者共12673例(TNFi 7748例,61%;JAKi 4925例,39%),评估基线心血管结局及癌症危险因素患病率。TNFi 组与 JAKi 组高危风险患病率均为26%。高危患者中至少一项主要可改变危险因素的患病率在 JAKi 组为79% vs 58%(PD 21%,95%CI 18%-24%),TNFi 组为81% vs 60%(PD 21%,95%CI 19%-23%)。

要点

  • TNFi组与JAKi组高危心血管/癌症风险患病率均为26%。
  • JAKi组高危 vs 低危患者至少一项可改变危险因素患病率79% vs 58%(PD 21%,95%CI 18%-24%)。
  • TNFi组高危 vs 低危患者至少一项可改变危险因素患病率81% vs 60%(PD 21%,95%CI 19%-23%)。

核心结论

  • 近年来在商业保险的类风湿关节炎患者中,JAKi与TNFi用于心血管及癌症风险升高患者的比例相似。
  • 作者认为,由于未控制疾病、可改变合并症及JAKi治疗与这些不良事件相关,未来评估安全数据出现后实践模式如何变化的研究将有价值。

研究设计与样本

  • 横断面研究,数据来自Merative MarketScan Commercial and Medicare数据库。
  • 纳入2019年8月16日至2022年3月31日期间首次 dispensing TNFi 或 JAKi 的类风湿关节炎患者,索引日期为首次 dispensing 日期,基线危险因素在索引日期前连续合格12个月的患者中评估。
  • 共12673例患者符合纳入标准:TNFi组7748例(61%),JAKi组4925例(39%)。

主要发现

  • 高危风险(年龄≥65岁、吸烟、或主要不良心血管事件、静脉血栓栓塞或癌症病史)患病率在TNFi组为26%(n=2051),JAKi组为26%(n=1262)。
  • 至少一项主要可改变危险因素(高血压、高脂血症、肥胖、糖尿病)在高危 vs 低危患者中的患病率:JAKi组79% vs 58%(PD 21%,95%CI 18%-24%)。
  • 至少一项主要可改变危险因素在高危 vs 低危患者中的患病率:TNFi组81% vs 60%(PD 21%,95%CI 19%-23%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The study was to determine the prevalence of baseline risk factors for cardiovascular outcomes and cancer among commercially-insured patients with rheumatoid arthritis (RA) during their first dispensed treatment for either tumor necrosis factor inhibitors (TNFi) or JAK inhibitors (JAKi). METHODS: Patients with RA from August 16, 2019 to March 31, 2022 were identified in the Merative MarketScan Commercial and Medicare databases. The first date that a TNFi or JAKi was dispensed was the index date, and baseline risk factors were assessed among patients continuously eligible for 12 months before the index date. Patients who had the following were stratified into an elevated risk category: age ≥65 years, smoking, or a history of a major adverse cardiovascular event, venous thromboembolism, or cancer. The prevalence of modifiable risk factors was also reported: hypertension, hyperlipidemia, obesity, and diabetes. The crude prevalence and prevalence difference (PD) were reported. RESULTS: A total of 12,673 patients (TNFi [n = 7,748; 61%] and JAKi [n = 4,925; 39%]) met inclusion criteria. The prevalence of elevated risk was the same for all patients using TNFi (n = 2,051; 26%) and JAKi (n = 1,262; 26%). Compared with patients having low risk, patients with an elevated risk also had a higher prevalence of at least one primary modifiable risk factor for both patients using JAKi (79% vs 58%; PD 21%, 95% confidence interval [CI] 18%-24%) and TNFi (81% vs 60%; PD 21%, 95% CI 19%-23%). CONCLUSION: In recent years, JAKi and TNFi were used in similar proportions to treat RA among commercially-insured patients at elevated cardiovascular and cancer risk. Because uncontrolled disease, modifiable comorbidities, and treatment with JAKi are associated with these adverse events, future studies evaluating how practice patterns may be affected by the emergence of safety data will be of value.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Janak JC, Ross RD, Brady BL, et al. Prevalence of Cardiovascular and Cancer Risk Factors Among Rheumatoid Arthritis Patients Prescribed JAK Inhibitors and Tumor Necrosis Factor Inhibitors: A Cross-Sectional Study. Arthritis Care Res (Hoboken). 2024. PMID: 38682605. doi:10.1002/acr.25356

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。